Home
/
Blood Sugar & Metabolic

Insulin Test: What It Measures & How to Read Results

REVIEWED BY
William Maish, MD MBA MPH
Clinical Product Lead
Published
April 18, 2026
Last updated
June 3, 2026
Key takeaway:

An insulin test measures the hormone that regulates blood sugar, not blood sugar itself. Fasting insulin levels between 2.6 and 24.9 µU/mL are typically within range, but levels above 15–20 µU/mL may indicate insulin resistance even when blood sugar remains normal. Insulin sensitivity can decline years before glucose levels rise out of range.

Read more →
Table of contents

What an insulin test means

An insulin test measures the amount of insulin circulating in your blood at the moment of testing. Think of insulin as your body's storage manager for glucose. When you eat, your blood sugar rises, and insulin rushes in to unlock your cells so they can absorb that glucose for energy.

The test itself is straightforward: a blood draw that measures insulin in microunits per milliliter (μU/mL). But here's where it gets interesting. Your insulin levels fluctuate dramatically throughout the day, spiking after meals and dropping during fasting periods.

Most insulin tests are performed fasting, meaning you haven't eaten for 8-12 hours. This gives your care team a baseline reading of how much insulin your pancreas produces when it's not actively responding to food. Fasting insulin levels between 2.6-24.9 μU/mL are typically considered within range, though optimal levels often fall in the lower half of this spectrum.

Some providers also order post-meal insulin tests or glucose tolerance tests that measure insulin response to a sugar challenge. These reveal how efficiently your insulin system responds to actual glucose loads, providing insight into early insulin resistance that fasting tests might miss.

How to interpret your insulin test

Reading your insulin test requires context about timing, other biomarkers, and your individual health picture. Elevated fasting insulin may be associated with insulin resistance, where your cells have become less responsive to insulin's signals. Your pancreas compensates by producing more insulin to achieve the same blood sugar control.

Here's the practical interpretation framework: Low fasting insulin (under 5 μU/mL) combined with normal blood sugar suggests good insulin sensitivity. Moderate levels (5-15 μU/mL) are often normal but warrant monitoring alongside glucose and hemoglobin A1c trends. High fasting insulin (above 15-20 μU/mL) may indicate insulin resistance, even if blood sugar remains normal.

Your care team might calculate additional ratios using your insulin results. The HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) combines fasting glucose and insulin to estimate insulin resistance. Values above 2.5 suggest significant insulin resistance, while levels below 1.0 indicate good insulin sensitivity.

Don't interpret insulin results in isolation. The pattern matters more than any single number. Rising insulin trends over time, especially when paired with gradually increasing glucose or A1c levels, may reveal metabolic changes before diabetes diagnosis criteria are met.

What can influence your insulin test

Multiple factors can shift your insulin levels, making timing and preparation crucial for accurate results. Food intake has the most dramatic effect. Even small amounts of calories can trigger insulin release, which is why most insulin tests require 8-12 hours of fasting.

Stress significantly impacts insulin through cortisol release. Both acute stress (illness, intense exercise, emotional trauma) and chronic stress (poor sleep, ongoing work pressure) can elevate insulin levels. Exercise timing matters too: intense workouts within 24 hours of testing can temporarily lower insulin sensitivity.

Medications alter insulin levels in predictable ways. Metformin typically lowers insulin by improving sensitivity. Steroids like prednisone raise insulin levels by promoting insulin resistance. Some blood pressure medications can also affect insulin sensitivity.

Body composition plays a role beyond weight alone. Visceral fat is particularly associated with insulin resistance, while muscle mass generally improves insulin sensitivity. Insulin sensitivity can also shift with age and hormonal changes.

Related context that changes the picture

Insulin test results gain meaning when viewed alongside related biomarkers that reveal the complete metabolic story. Glucose levels provide the other half of the blood sugar equation. Normal glucose with high insulin suggests early insulin resistance, while high glucose with low insulin might indicate pancreatic dysfunction.

Hemoglobin A1c shows your average blood sugar over 2-3 months, revealing patterns that single-point insulin tests might miss. Rising A1c trends combined with increasing insulin levels track the progression from insulin resistance toward type 2 diabetes.

Advanced lipid markers often shift alongside insulin resistance. High triglycerides, low HDL cholesterol, and elevated triglyceride-to-HDL ratios frequently accompany elevated insulin levels. These patterns together suggest metabolic syndrome, a cluster of conditions that increase cardiovascular and diabetes risk.

Inflammatory markers like C-reactive protein (CRP) and liver enzymes can provide additional context. Chronic inflammation contributes to insulin resistance, while fatty liver often develops alongside insulin resistance. Thyroid function also influences insulin sensitivity, with both hyperthyroidism and hypothyroidism affecting glucose metabolism.

Take control of your metabolic health

Understanding your insulin levels is just the beginning. The real power comes from tracking these patterns over time alongside complementary markers that reveal your complete metabolic picture.

Superpower's Metabolic Health Panel includes insulin testing alongside glucose, hemoglobin A1c, and comprehensive lipid analysis to give you and your care team the complete data needed for early intervention. Our Advanced Blood Panel goes even deeper, adding insulin resistance calculations and additional hormonal markers that influence metabolism.

Measure your insulin levels and metabolic markers today to catch changes before they become problems.

FAQs

Normal fasting insulin levels typically range from 2.6-24.9 μU/mL, though optimal levels often fall in the lower half of this range (under 10-12 μU/mL). Levels above 15-20 μU/mL may indicate insulin resistance, even with normal blood sugar.

High insulin with normal blood sugar often indicates early insulin resistance. Your pancreas produces extra insulin to maintain normal glucose levels because your cells aren't responding efficiently to insulin's signals. This pattern can precede type 2 diabetes by years.

Most insulin tests require 8-12 hours of fasting for accurate results. Even small amounts of food can trigger insulin release and significantly affect your results. Your care team may occasionally order post-meal insulin tests for specific diagnostic purposes.

Yes, both acute and chronic stress can elevate insulin levels through cortisol release. Illness, intense exercise, poor sleep, or emotional stress within 24-48 hours of testing can temporarily raise insulin levels and affect interpretation.

Glucose tests measure blood sugar levels directly, while insulin tests measure the hormone that regulates blood sugar. Insulin sensitivity often declines years before glucose levels rise, making insulin testing valuable for early detection of metabolic dysfunction.

HOMA-IR combines fasting glucose and fasting insulin to estimate insulin resistance. A score below 1.0 suggests good insulin sensitivity, while values above 2.5 indicate significant resistance. This calculated ratio often reveals insulin resistance patterns that neither marker alone can detect.

References

  1. Tabák, A. G., Jokela, M., Akbaraly, T. N., Brunner, E. J., Kivimäki, M., & Witte, D. R. (2009). Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet (London, England), 373(9682), 2215-21. https://doi.org/10.1016/S0140-6736(09)60619-X
  2. Pratley, R. E., & Weyer, C. (2001). The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia, 44(8), 929-45. https://doi.org/10.1007/s001250100580
  3. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7), 412-9. https://doi.org/10.1007/BF00280883
  4. Bailey, C. J. (2017). Metformin: historical overview. Diabetologia, 60(9), 1566-1576. https://doi.org/10.1007/s00125-017-4318-z
  5. D'Elia, J. A., & Weinrauch, L. A. (2023). Hyperglycemia and Hyperlipidemia with Kidney or Liver Transplantation: A Review. Biology, 12(9). https://doi.org/10.3390/biology12091185
  6. Blüher, M. (2013). Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best practice & research. Clinical endocrinology & metabolism, 27(2), 163-77. https://doi.org/10.1016/j.beem.2013.02.005
  7. Blum, M. R., Popat, R. A., Nagy, A., Cataldo, N. A., & McLaughlin, T. L. (2021). Using metabolic markers to identify insulin resistance in premenopausal women with and without polycystic ovary syndrome. Journal of endocrinological investigation, 44(10), 2123-2130. https://doi.org/10.1007/s40618-020-01430-2
  8. Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J. C., James, W. P., Loria, C. M., Smith, S. C., International Diabetes Federation Task Force on Epidemiology and Prevention, Hational Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, & International Association for the Study of Obesity (2009). Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120(16), 1640-5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
  9. Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G. (2010). Epidemiology of non-alcoholic fatty liver disease. Digestive diseases (Basel, Switzerland), 28(1), 155-61. https://doi.org/10.1159/000282080

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey